Skip to main content

Behandlung von Oligometastasen durch stereotaktisch-ablative Strahlentherapie oder Resektion beim metastasierten hormonsensitiven Prostatakarzinom

Kommentar zur systematischen Übersichtsarbeit über prospektive klinische Studien

Treatment of oligometastases by stereotactic ablative radiotherapy or resection in metastatic hormone-sensitive prostate cancer

Comments on the systematic review article about prospective clinical studies

This is a preview of subscription content, access via your institution.

Literatur

  1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746

    CAS  Article  Google Scholar 

  2. Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13–24

    CAS  Article  Google Scholar 

  3. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121–131

    CAS  Article  Google Scholar 

  4. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360

    CAS  Article  Google Scholar 

  5. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132–1142

    CAS  Article  Google Scholar 

  6. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2021) S3-Leitlinie Prostatakarzinom L. AWMF Registernummer 043/022OL

    Google Scholar 

  7. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366

    Article  Google Scholar 

  8. Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU (2020) Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol 17(3):168–182

    Article  Google Scholar 

  9. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):4078–4101

    Article  Google Scholar 

  10. UK SABR Consortium (2019) Stereotactic ablative body radiation therapy (SABR): a resource UK SABR consortium (v.6.1)

    Google Scholar 

  11. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453

    CAS  Article  Google Scholar 

  12. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659

    Article  Google Scholar 

  13. Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74(4):455–462

    Article  Google Scholar 

  14. O’Shaughnessy MJ, McBride SM, Vargas HA, Touijer KA, Morris MJ, Danila DC et al (2017) A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology 102:164–172

    Article  Google Scholar 

  15. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357

    CAS  Article  Google Scholar 

  16. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 162(2):454

    CAS  Article  Google Scholar 

  17. Linxweiler J, Hajili T, Zeuschner P, Menger MD, Stöckle M, Junker K et al (2022) Primary tumor resection decelerates disease progression in an orthotopic mouse model of metastatic prostate cancer. Cancers (Basel) 14(3):737

    CAS  Article  Google Scholar 

  18. Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM (2017) Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 14(1):15–25

    CAS  Article  Google Scholar 

  19. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208–1216

    CAS  Article  Google Scholar 

  20. Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX et al (2021) Oligometastatic disease detection with (68)Ga-PSMA-11 PET/CT in hormone-sensitive prostate cancer patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical. Impact Cancers (Basel) 13(19):4982

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angelika Borkowetz.

Ethics declarations

Interessenkonflikt

A. Borkowetz gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Die Zusammenfassung ist eine Übersetzung des Abstracts der Originalpublikation

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Borkowetz, A. Behandlung von Oligometastasen durch stereotaktisch-ablative Strahlentherapie oder Resektion beim metastasierten hormonsensitiven Prostatakarzinom. Urologie (2022). https://doi.org/10.1007/s00120-022-01861-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00120-022-01861-0